This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

EVOLUTION® Duodenal Stent for Duodenal or Gastric Outlet Obstruction Caused by Malignant Neoplasms

This study has been completed.
Information provided by (Responsible Party):
Cook Group Incorporated Identifier:
First received: August 13, 2009
Last updated: March 28, 2012
Last verified: March 2012
The objective of this investigation is to compile clinical experience on the use of the Evolution® Duodenal Stent (Cook Ireland), a CE marked device intended for the palliative treatment of duodenal or gastric outlet obstruction and duodenal strictures caused by malignant neoplasms. It is not the goal to change the usual treatment practice of the investigator or the center, nor to collect information on uses outside the product's indications. Patients will be treated as per usual medical practices.

Condition Intervention
Duodenal Obstruction Gastric Outlet Obstruction Device: EVOLUTION® Duodenal Stent

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Treatment of Duodenal or Gastric Outlet Obstruction and Duodenal Strictures Caused by Malignant Neoplasms With the EVOLUTION® Duodenal Stent

Further study details as provided by Cook Group Incorporated:

Primary Outcome Measures:
  • Patency of the stent [ Time Frame: 14 days ]

Secondary Outcome Measures:
  • Procedural success, implant duration, symptom resolution [ Time Frame: up to 6 months ]

Enrollment: 110
Study Start Date: December 2009
Study Completion Date: March 2012
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
EVOLUTION® Duodenal Stent Device: EVOLUTION® Duodenal Stent
EVOLUTION® Duodenal Stent
Other Name: TC325


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who are referred into regional specialty centers for treatment of GI malignancy.

Inclusion Criteria:

  • Patients for whom this device would be chosen in standard practice

Exclusion Criteria:

  • Patients for whom this device would not normally be chosen in standard practice
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00991614

Westmead Hospital
Sydney, Australia, 2145
Canada, Quebec
Hopital Saint-Luc / CHUM
Montreal, Quebec, Canada, H2X3J4
Czech Republic
Institution for Clinical and Experimental Medicine
Praha, Czech Republic
IRCCS Instituto Clinico Humanitas
Milan, Italy, 20089
U.O. Endoscopia Digestiva Chirurgica
Rome, Italy, 00168
Erasmus MC University Medical Center
Rotterdam, Netherlands, 3015 CE
Sponsors and Collaborators
Cook Group Incorporated
Principal Investigator: Professor Guido Costamagna, MD U.O. Endoscopia Digestiva Chirurgica
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Cook Group Incorporated Identifier: NCT00991614     History of Changes
Other Study ID Numbers: 09-005
Study First Received: August 13, 2009
Last Updated: March 28, 2012

Additional relevant MeSH terms:
Gastric Outlet Obstruction
Pyloric Stenosis
Duodenal Obstruction
Stomach Diseases
Gastrointestinal Diseases
Digestive System Diseases
Duodenal Diseases
Intestinal Diseases
Intestinal Obstruction processed this record on August 23, 2017